Fundraising Fox
/Companies
Sign in

Osmol Therapeutics

New Haven, US · Founded 2016 · Delaware corporation · 6 employees on LinkedIn · 1 known investors

Find your way into Osmol Therapeutics

Sign up to see every warm intro you have to Osmol Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Osmol Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Osmol Therapeutics is a preclinical-stage biotech developing OSM-0205, an intravenous drug intended to prevent chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) in cancer patients receiving taxane-based therapy. The drug targets the interaction that triggers a calcium surge leading to neuronal damage, aiming to allow optimal chemotherapy dosing.

BiotechHealthtech

Founders & leadership

BD
Brian DixonExecutive
BLBob Linke
Bob LinkePresident & CEOBob Linke is President and CEO of Osmol Therapeutics, a preclinical biotech company developing a therapeutic to prevent chemotherapy-induced neuronal damage. He has held CEO positions in biopharmaceutical companies, raising capital for development programs, and brings prior experience from large pharmaceutical organizations.
RW
Ron WeitzmanChief Medical Officer

Board

BE
Barbara EhrlichChief Scientific Advisor

Investors · 1

Reported raises · per SEC filings

Form D private placements

$2.9M disclosed across 2 rounds · 2016–2022

▶$2.3MraisedFeb 2022 · 4 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Michael EhrlichDirector
  • Robert BermanDirector
  • Robert LinkeExecutive Officer, Director
  • Vlad CoricDirector
Offering amount
$7.5M
Amount sold
$2.3M
First sale
Feb 2022
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$550KraisedJan 2017 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Brian DixonExecutive Officer, Director
Offering amount
$3M
Amount sold
$550K
First sale
Dec 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

OS TherapiesOS Therapies (OST) is a clinical-stage cancer immunotherapy company developing treatments that activate the immune system to target HER2-expressing cancers, initially focusing on osteosarcoma in children and adults. It plans to expand its lead candidate into breast, colorectal, esophageal, lung, ovarian, and pancreatic cancers and other solid tumors.
Applied TherapeuticsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.

Companies working in the same space as Osmol Therapeutics.

Frequently asked questions

What does Osmol Therapeutics do?
Osmol Therapeutics is a preclinical-stage biotech developing OSM-0205, an intravenous drug intended to prevent chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) in cancer patients receiving taxane-based therapy. The drug targets the interaction that triggers a calcium surge leading to neuronal damage, aiming to allow optimal chemotherapy dosing.
Who are Osmol Therapeutics's investors?
Osmol Therapeutics's investors include Elm Street Ventures.
How much funding has Osmol Therapeutics raised?
Osmol Therapeutics has disclosed $2.9M raised across 2 rounds.
Where is Osmol Therapeutics headquartered?
Osmol Therapeutics is headquartered in New Haven, US.